IFI35, mir-99a and HCV Genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Estrabaud, Emilie ^a,b,c,d   Appourchaux, Kevin ^a,b,c,d   Bièche, Ivan ^e   Carrat, Fabrice ^f   Lapalus, Martine ^a,b,c,d   Lada, Olivier ^a,b,c,d   Martinot Peignoux, Michelle ^a,b,c,d   Boyer, Nathalie ^a,b,c,d   Marcellin, Patrick ^a,b,c,d   Vidaud, Michel ^e   Asselah, Tarik ^a,b,c,d  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BEAUJON HOSPITAL   (France)

^d Laboratory of Excellence Labex INFLAMEX   (France)

^e FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^f HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; INTERFERON INDUCIBLE PROTEIN 35; MESSENGER RNA; MICRORNA; MICRORNA 181A; MICRORNA 217; MICRORNA 23A; MICRORNA 99A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IFI35 PROTEIN, HUMAN; INTERFERON; MIRN99 MICRORNA, HUMAN; RIBAVIRIN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; DOWN REGULATION; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IFNL3 GENE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUSTAINED VIROLOGICAL RESPONSE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; METABOLISM; MIDDLE AGED; VIROLOGY; VIRUS GENOME; YOUNG ADULT;

HEPATITIS C VIRUS;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; MALE; MICRORNAS; MIDDLE AGED; RIBAVIRIN; YOUNG ADULT;

EID: 84927517553     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121395     Document Type: Article

References (49)

1. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002; 36: S47-S56. PMID: 12407576.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002; 36: S35-S46. PMID: 12407575.
3. Asselah T, Marcellin P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int. 2014; 34 Suppl 1: 60-68. doi:10.1111/liv.12424PMID:24373080.
4. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: The best interferonfree combinations. Liver Int. 2014; 34 Suppl 1: 69-78. doi:10.1111/liv.12423 PMID: 24373081.
5. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol. 2012;.
6. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut. 2008; 57: 516-524. PMID: 17895355.
7. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005; 128: 1437-1444. PMID: 15887125.
8. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology. 2005; 42: 702-710. PMID: 16108059.
9. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008; 105: 7034- 7039. doi:10.1073/pnas.0707882105 PMID: 18467494.
10. Asselah T, De-Muynck S, Broet P, Masliah-Planchon J, Blanluet M, Bieche I, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2011; 56: 527-532. doi:10.1016/j.jhep.2011.09.008 PMID: 21951981.
11. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401. doi:10.1038/nature08309 PMID: 19684573.
12. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004; 431: 343- 349. PMID: 15372041.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297. PMID: 14744438.
14. Peng X, Li Y, Walters KA, Rosenzweig ER, Lederer SL, Aicher LD, et al. Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics. 2009; 10: 373. doi:10.1186/1471-2164-10-373 PMID: 19671175.
15. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009; 49: 1098-1112. doi:10.1002/hep.22749 PMID: 19173277.
16. Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, Tajima A, et al. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics. 2010; 3: 48. doi:10.1186/1755-8794-3-48 PMID: 20969775.
17. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007; 449: 919-922. PMID: 17943132.
18. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005; 309: 1577-1581. PMID: 16141076.
19. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of micro- RNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008; 36: 1153-1162. PMID: 18158304.
20. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368: 1685-1694. doi:10.1056/NEJMoa1209026PMID: 23534542.
21. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010; 327: 198-201. doi:10.1126/science.1178178 PMID: 19965718.
22. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 2009; 15: 31- 33. doi:10.1038/nm.1902 PMID: 19122656.
23. Estrabaud E, Lapalus M, Broet P, Appourchaux K, De Muynck S, Lada O, et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol. 2014; 88: 6394-6402. doi:10.1128/JVI.00016-14 PMID: 24672032.
24. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-1444. doi:10.1002/hep.24641 PMID: 21898493.
25. EASL. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55: 245-264. doi:10.1016/j.jhep.2011.02.023 PMID: 21371579.
26. Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, Degott C, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology. 2005; 129: 2064-2075. PMID: 16344072.
27. Bieche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology. 2005; 332: 130-144. PMID: 15661146.
28. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24: 289-293. PMID: 8690394.
29. Asselah T, Bieche I, Laurendeau I, Martinot-Peignoux M, Paradis V, Vidaud D, et al. Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue. Hepatology. 2008; 48: 953-962. doi:10.1002/hep.22411 PMID: 18726958.
30. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001; 54: 774-781. PMID: 11470385.
31. Li D, Liu X, Lin L, Hou J, Li N, Wang C, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 2011; 286: 36677-36685. doi:10.1074/jbc.M111.270561 PMID: 21878637.
32. Wang B, Hsu S, Frankel W, Ghoshal K, Jacob ST. Stat3-mediated activation of miR-23a suppresses gluconeogenesis in hepatocellular carcinoma by downregulating G6PC and PGC-1alpha. Hepatology. 2012;.
33. Zhou B, Li C, Qi W, Zhang Y, Zhang F, Wu JX, et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia. 2012; 55: 2032-2043. doi:10.1007/s00125-012-2539-8 PMID: 22476949.
34. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012; 482: 347-355. doi:10.1038/nature10888 PMID: 22337054.
35. De-Yebenes VG, Bartolome-Izquierdo N, Nogales-Cadenas R, Perez-Duran P, Mur SM, Martinez N, et al. miR-217 is an oncogene that enhances the germinal center reaction. Blood. 2014; 124: 229-239. doi:10.1182/blood-2013-12-543611 PMID: 24850757.
36. Turcatel G, Rubin N, El-Hashash A, Warburton D. MIR-99a and MIR-99b modulate TGF-beta induced epithelial to mesenchymal plasticity in normal murine mammary gland cells. PLoS One. 2012; 7: e31032. doi:10.1371/journal.pone.0031032 PMID: 22299047.
37. Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu M, et al. MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor. Febs J. 2010; 277: 3726- 3734. doi:10.1111/j.1742-4658.2010.07773.x PMID: 20698883.
38. Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, et al. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology. 2007; 46: 1016-1025. PMID: 17668881.
39. Gelley F, Zadori G, Nemes B, Fassan M, Lendvai G, Sarvary E, et al. MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis. J Gastroenterol Hepatol. 2014; 29: 121-127. doi:10.1111/jgh.12362 PMID: 24033414.
40. Akamatsu S, Hayes CN, Tsuge M, Miki D, Akiyama R, Ochi H, et al. Differences in serum microRNA profiles in hepatitis B and C virus infection. J Infect. 2014;.
41. Yang Z, Chen H, Si H, Li X, Ding X, Sheng Q, et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol. 2014; 51: 823-831. doi:10.1007/s00592-014-0617-8 PMID: 24981880.
42. Das A, Dinh PX, Panda D, Pattnaik AK. Interferon-inducible protein IFI35 negatively regulates RIG-I antiviral signaling and supports vesicular stomatitis virus replication. J Virol. 2014; 88: 3103-3113. doi:10.1128/JVI.03202-13 PMID: 24371060.
43. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011; 54: 1094-1101. doi:10.1016/j.jhep.2010.09.019 PMID: 21145800.
44. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2010; 140: 1021-1031. doi:10.1053/j.gastro.2010.11.039 PMID: 21111740.
45. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010; 139: 499-509. doi:10.1053/j.gastro.2010.04.049 PMID: 20434452.
46. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010; 52: 1888-1896. doi:10.1002/hep.23912 PMID: 20931559.
47. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010; 139: 120-129 e118. doi:10.1053/j.gastro.2010.04.013 PMID: 20399780.
48. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011; 54: 415-421. doi:10.1016/j.jhep.2010.07.041 PMID: 21112657.
49. Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. J Hepatol. 2014; 61: 193-195. doi:10.1016/j.jhep.2014.03.006 PMID: 24650692.